Why Flies? Inside Future Fields' Bet on Insect-Based Protein Manufacturing

For protein expression teams, the toolkit has looked roughly the same for half a century: E. coli, yeast, and mammalian cell lines like CHO. It works, but it's slow, expensive, and fragile when a protein doesn't behave. Future Fields, a biomanufacturing company out of Edmonton, thinks the industry has been confining itself to a handful of systems for too long, and it's built an alternative around an unlikely host: the fruit fly.

Future Fields' platform, EntoEngine, uses Drosophila melanogaster as a recombinant protein expression system, targeting the difficult-to-express proteins (DTEPs) that give traditional systems the most trouble. The company sponsored SynBioBeta's biopharma dinner this year, and CEO and co-founder Matt Anderson-Baron, PhD, sat down with us to explain why insects, why now, and what it means for pharma teams stuck waiting on cell lines that won't cooperate.

From Cultivated Meat to First Principles

Anderson-Baron's path into synthetic biology started in grad school, through cellular agriculture. He was drawn to the idea of biology as a tool for building physical things, and building them better. That premise became the foundation for Future Fields, which started out making growth factors for cultivated meat before expanding into custom proteins for agrisciences, drug developers, and beyond.

The shift toward Drosophila wasn't a single eureka moment. It was what Anderson-Baron describes as a forcing function: the growth factor problem in cultivated meat pushed him to look closely at protein manufacturing, and he was surprised to find that after 50 years of recombinant technology, the field still relies on a small set of expression systems, most of them single cells that need expensive steel-tank infrastructure to grow.

So the Future Fields team ran the exercise in reverse. Instead of picking a host and working around its limits, they described the features of an ideal manufacturing system first, then asked which organism could deliver them. Every time, the answer came back the same: Drosophila.

The Pitch to Pharma: Speed, Resilience, Cost

Anderson-Baron points to three advantages that matter most for pharma protein expression teams.

Speed to scale. Traditional systems can take 18 to 24 months and millions of dollars to scale, largely because stable mammalian cell lines are difficult to establish and require constant re-optimization of sparging rate, oxygen transfer, and media composition as batch size changes. EntoEngine uses the same infrastructure, media, and growth conditions to scale every protein, cutting the sequence-to-scaled-process timeline to under seven months.

Supply chain resilience. Insects tolerate perturbations that would crash a cell culture, so contamination, expression loss, and genetic drift, the risks that keep pharma supply chain teams up at night, aren't the same threat. Future Fields' strains stay genetically stable indefinitely, and biomass can be frozen and stockpiled ahead of manufacturing runs, adding a buffer that shortens turnaround when demand spikes.

Cost-effective complexity. Insects are cheaper to rear than mammalian cells across inputs, infrastructure, and timeline, and they're well suited to producing complex proteins. As Anderson-Baron puts it, the goal is the complexity of a CHO system at the cost of E. coli.

What's Next: 200x Scale-Up and New Verticals

Future Fields has large-scale contracts to fulfill in late 2026 and into 2027 that will require scaling 200 times beyond the company's biggest runs to date. Execution is the near-term priority, alongside expansion into cell therapy and in vitro diagnostics (IVD), two markets Anderson-Baron sees as having steep growth trajectories and unmet protein needs. The company is also working through a roadmap to ISO 13485 and GMP compliance in the coming months.

As for obstacles, Anderson-Baron argues the hardest technical problems are largely solved. The EntoEngine has expressed roughly 50 proteins so far, but protein biochemistry spans millions of possible sequences. The open question isn't whether Drosophila can express a given protein, it's which proteins Future Fields is uniquely positioned to solve for, and which of those map to real market need. E. coli, CHO, and yeast have had roughly 50 years of development behind them. Future Fields has had six.

Who This Is For

Future Fields is looking to reach anyone at a pharma company who needs proteins, particularly Discovery and Exploratory teams, along with cell therapy companies, IVD companies, and other life sciences organizations with protein manufacturing needs. The company's core message to that audience: EntoEngine isn't a risky new technology, it's a derisked option, proven across dozens of proteins and built to solve the expression problems that legacy systems can't.

Protein expression teams evaluating options can reach out directly to Matt Anderson-Baron at matt@futurefields.io to set up a discovery call.